Analysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Price Target at $12.33

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) have been given an average recommendation of “Buy” by the six brokerages that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $12.33.

A number of analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Rani Therapeutics in a research report on Friday, February 7th. Canaccord Genuity Group reissued a “buy” rating and issued a $9.00 price target on shares of Rani Therapeutics in a research report on Wednesday, February 26th.

Insider Buying and Selling

In other Rani Therapeutics news, insider Kate Mckinley purchased 17,960 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was bought at an average cost of $1.67 per share, for a total transaction of $29,993.20. Following the completion of the transaction, the insider now owns 17,960 shares in the company, valued at approximately $29,993.20. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 53.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Two Sigma Advisers LP bought a new position in Rani Therapeutics during the 4th quarter worth approximately $151,000. Two Sigma Investments LP bought a new position in shares of Rani Therapeutics in the fourth quarter valued at approximately $399,000. Insigneo Advisory Services LLC bought a new position in shares of Rani Therapeutics during the fourth quarter valued at about $65,000. Takeda Pharmaceutical Co. Ltd. bought a new stake in Rani Therapeutics during the fourth quarter worth $278,000. Finally, Virtu Financial LLC bought a new position in Rani Therapeutics during the fourth quarter valued at about $62,000. 30.19% of the stock is currently owned by institutional investors.

Rani Therapeutics Stock Down 1.3 %

RANI opened at $1.56 on Wednesday. The stock’s fifty day moving average is $1.48 and its 200-day moving average is $2.01. The company has a market capitalization of $89.37 million, a PE ratio of -1.47 and a beta of 0.14. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.60 and a current ratio of 1.60. Rani Therapeutics has a one year low of $1.24 and a one year high of $8.75.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.